Discovery of Trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as Potent, Orally Bioavailable TGR5 (GPBAR1) Agonists: Structure–Activity Relationships, Lead Optimization, and Chronic In Vivo Efficacy
摘要:
Activation of the G-protein coupled receptor (GPCR) Takeda G-protein receptor 5 (TGR5), also known as G-protein bile acid receptor 1 (GPBAR1), has been shown to play a key role in pathways associated with diabetes, metabolic syndrome, and autoimmune disease. Nipecotamide 5 was identified as an attractive starting point after a high-throughput screen (HTS) for receptor agonists. A comprehensive hit-to-lead effort culminated in the discovery of 45h as a potent, selective, and bioavailable TGR5 agonist to test in preclinical metabolic disease models. In genetically obese mice (ob/ob), 45h was as effective as a dipeptidyl peptidase-4 (DPP-4) inhibitor at reducing peak glucose levels in an acute oral glucose tolerance test (OGTT), but this effect was lost upon chronic dosing.
[EN] 3-PYRIDINYLETHYLBENZAMIDE DERIVATIVES AS FUNGICIDES<br/>[FR] DERIVES DE 3-PYRIDINYLETHYLBENZAMIDE EN TANT QUE FONGICIDES
申请人:BAYER CROPSCIENCE SA
公开号:WO2006008191A1
公开(公告)日:2006-01-26
Compound of general formula (I). Process for preparing this compound. Intermediate of general formula (II) to prepare compound of formula (I). Intermediate of general formula (V) to prepare compound of formula (I). Fungicidal composition comprising a compound of general formula (I). Method for treating plants by applying a compound of general formula (I) or a composition comprising it.
3-Pyridinylethylbenzamide Derivatives as Fungicides
申请人:Mansfield Darren
公开号:US20080033020A1
公开(公告)日:2008-02-07
Compound of general formula (I):
Process for preparing this compound.
Intermediate of general formula (II) to prepare compound of formula (I)
Intermediate of general formula (V) to prepare compound of formula (I):
Fungicidal composition comprising a compound of general formula (I). Method for treating plants by applying a compound of general formula (I) or a composition comprising it.
The exploration of pharmaceutically active agents and positronemissiontomography (PET) tracers targeting CXCR4 has been a focal point in cancer research given its pivotal role in the development and progression of various cancers. While significant strides have been made in PETimaging with radiometal-labeled tracers, the landscape of 18F-labeled small molecule tracers remains relatively limited
鉴于 CXCR4 在各种癌症的发生和发展中起着关键作用,针对 CXCR4 的药物活性剂和正电子发射断层扫描 (PET) 示踪剂的探索一直是癌症研究的重点。虽然使用放射性金属标记示踪剂进行 PET 成像取得了重大进展,但 18种 F 标记的小分子示踪剂的情况仍然相对有限。在此,我们介绍了一种新颖且有前途的衍生物 [18F]SFB-AMD3465,作为 CXCR4 的靶向 PET 示踪剂。该化合物是通过修饰 AMD3465 的吡啶环合成的,随后使用 [18F] SFB 用 18F 标记。该研究为 [18F]SFB-AMD3465 的设计、合成和生物学评估提供了全面的见解。体外和体内评估表明,在 CXCR4 过表达的 4T1 细胞系和相应的携带异种移植物的小鼠模型中,[18F]SFB-AMD3465 的 CXCR4 依赖性、特异性和敏感性摄取。这些发现有助于弥合 18种 F 标记的 PET 示踪剂中用于